11月25日,丹麦胰岛素巨头诺和诺德公布了口服司美格鲁肽针对早期症状性阿尔茨海默病的III期evoke 和evoke+临床试验的两年期主要分析结果。由于未能达到目标,该股下挫逾10%。 这是疯狂了三年的“减肥神药”司美格鲁肽首次遇挫。司美格鲁肽(Ozempic/Wegovy/Rybelsus)作为全球首个获批的GLP-1产品,适应症从糖尿病到体重管理,再到降低心血管不良事件风险以及非肝硬化性代谢...
Source Link11月25日,丹麦胰岛素巨头诺和诺德公布了口服司美格鲁肽针对早期症状性阿尔茨海默病的III期evoke 和evoke+临床试验的两年期主要分析结果。由于未能达到目标,该股下挫逾10%。 这是疯狂了三年的“减肥神药”司美格鲁肽首次遇挫。司美格鲁肽(Ozempic/Wegovy/Rybelsus)作为全球首个获批的GLP-1产品,适应症从糖尿病到体重管理,再到降低心血管不良事件风险以及非肝硬化性代谢...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.